Despite the fact that programmed cell death protein 1 (PD-1) inhibitors are effective in recurrent/metastatic NPC, the objective response rate is still poor at 22.5% [4, 5], and resistance to a single ICI therapy may develop over time. Here, PDCD1 is linked to nasopharyngeal carcinoma.